Navigation Links
New book reviews research on p53 -- the 'guardian of the genome' -- and its relatives
Date:6/23/2010

COLD SPRING HARBOR, N.Y. (June 23, 2010) -- The p53 tumor suppressor gene, the "guardian of the genome," protects cells against genotoxic stress but is mutated in many cancers. It encodes one of a family of proteins that regulate cell proliferation, differentiation, senescence, and cell death. Mutations in p53 allow cells to escape normal growth controls and thereby contribute to tumor malignancy.

A new book from Cold Spring Harbor Laboratory Press, The p53 Family, provides a comprehensive review of the functions of the p53 family. It was edited by Arnold Levine and David Lane, who independently discovered p53 about 30 years ago.

"We hope that by bringing together a unique gathering of experts this volume will provide a great introduction to the field for newcomers to the p53 family and a starting off point for vigorous debate among the converted," write Levine and Lane in the preface to the book. "The many unknowns in this system that are detailed and discussed in this volume provide us all with inspiration for future work."

In 23 chapters, the contributors examine the normal roles of these transcription factors, the regulatory mechanisms that control p53 activity, and the part played by p53 mutations in tumorigenesis. They also discuss the evolution of the p53 family, which may originally have arisen to protect the integrity of the germ line.

The p53 Family also covers the structure of p53 and its isoforms, model systems for analyzing p53 function, studies of p53 polymorphisms, and therapeutic approaches aimed at targeting p53 defects in cancer.


'/>"/>

Contact: Ingrid Benirschke
benirsch@cshl.edu
619-275-6021
Cold Spring Harbor Laboratory
Source:Eurekalert  

Page: 1

Related biology news :

1. New book reviews the structure and function of cell junctions
2. EPA reviews Univ. of Michigan dioxin study
3. Reviews of microbial gene language published in special issue of Trends in Microbiology
4. Biophysical Reviews makes debut in 2009
5. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
6. Researchers create self-assembling nanodevices that move and change shape on demand
7. UCI researchers develop worlds first plastic antibodies
8. Rice yields researched to tackle food security issues
9. Freely available data supporting next generation of human genetic research
10. NYU Langone Medical Center receives $5.4 million NYSTEM grant for stem cell research
11. Research on stem cells wins first prize for Hebrew University researcher
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New book reviews research on p53 -- the 'guardian of the genome' -- and its relatives
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... As drylands of the world become even drier, water will not ... the soil will likely be affected, and their imbalance could affect ... That includes people living in Arizona, who may be in for ... study published in Nature that details how soil changes ...
... teams at the Polytechnic Institute of New York University ... understand and influence the complex swimming behaviors of schooling ... of mechanical and aerospace engineering at NYU-Poly, published two ... These studies are the latest in a ...
... scent marking to advertise their territory they urinate at ... It has been suggested that markings serves to attract females ... males, scent marks appear to be a secondary sexual trait, ... mate. When male house mice are subordinate or sick, for ...
Cached Biology News:Plant production could decline as climate change affects soil nutrients 2The secret's in the (robotic) stroke 2The secret's in the (robotic) stroke 3Scent marking 2
(Date:5/28/2015)... , May 27, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Glenn Keet, ... The Changing Landscape of EMR/EHR Clinical Data Integration with ... taking place in Washington, DC on June 14th-18th. , ... of integrating EMR/EHR systems with EDC, and will examine ... brought by eSource and electronic health records/electronic medical records ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Visionsense Corp. announces,FDA 510(k) Clearance of ... The system is based on a miniature ... Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... MIS surgical,procedures that are under served by ...
... Therapeutics announced today,the initiation of a Phase ... orally bioavailable small molecule in development for ... I study will evaluate the safety,tolerability and ... blind, placebo controlled, single ascending dose design ...
... March 18 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... II study of,NGX267, a muscarinic agonist in development ... The company is conducting a randomized, double-blind,placebo-controlled, ... evaluate,the safety, tolerability and efficacy of this once-a-day ...
Cached Biology Technology:Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: